BVS
Bioventus Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▲ Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8%…
- Mar 5 ▲ Bioventus reported strong Q4 and full-year 2025 results with 10.0% o…
- Mar 11 ▼ 1 insider sell $105.4K at $8.79
- May 6 ▲ Bioventus reported Q1 2026 revenue of $132.1M (+7% YoY) and GAAP EPS…
- May 6 ▲ Bioventus reported Q1 2026 revenue of $132.1M (+6.6% YoY) and GAAP E…
- May 8 Jung Jae Hyung, Derivatively on Behalf of Bioventus Inc. v…
- Jun 2 ▼ Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus t…
- Aug 5 ▲ Bioventus reported Q2 2026 revenue of $153.2M (+4% YoY), slightly be…
- Nov 2 ▲ Earnings: BVS Q3 2026 Earnings: EPS $0.17 (+5.2% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $105.4K.
- InstitutionsMIXED
Q3 2026: 22 added (1 new), 15 trimmed or exited.
- AnalystsBULLISH
8 of 9 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −4.9% to 3.02M shares. 6.6 days to cover, ≈3.6% of shares.
- TrendDOWNTREND
20% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | $29.5M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $5.9M |
| FMR LLC | TRIM | $4.6M |
| FRANKLIN TEMPLETON INC | DOUBLED | $3.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $3.4M |
| Bank of New York Mellon Corp | ADD | $2.7M |
| SEI INVESTMENTS CO | DOUBLED | $2.3M |
| LPL Financial LLC | DOUBLED | $2.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
9 analystsPrice is below the lowest target. Median implies +53%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 3, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Aug 17, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Aug 17, 2026 | Cantor Fitzgerald REITERATE | Overweight |
| Jun 30, 2026 | Barrington Research MAINTAIN | Outperform |
| Jun 16, 2026 | Canaccord Genuity MAINTAIN | Buy |
| May 22, 2026 | Barrington Research MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
NEELS GUIDO J Director Jun 3, 2026 | AWARD | 25,146 sh |
Beyer Pat Director Jun 3, 2026 | AWARD | 25,146 sh |
Ladone Mary Kay Director Jun 3, 2026 | AWARD | 25,146 sh |
HAWKINS WILLIAM A Director Jun 3, 2026 | AWARD | 30,994 sh |
Cowdy Philip G. Director Jun 3, 2026 | AWARD | 25,146 sh |
STALNECKER SUSAN M Director Jun 3, 2026 | AWARD | 25,146 sh |
McMurry-Heath Michelle Director Jun 3, 2026 | AWARD | 25,146 sh |
SUTTER MARTIN P Director Jun 3, 2026 | AWARD | 25,146 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 1 press release · 6 bullish · 2 bearish · 1 mixed · 8 neutral- NEUTRAL SC 13GNov 13, 2026
Brown Advisory Inc. disclosed a 5.8% passive stake in Bioventus Inc. via Schedule 13G, reporting…
Brown Advisory's new 5.8% passive stake adds a large institutional holder to the register, but the passive certification limits near-term catalyst potential. Monitor the ongoing strategic…
- NEUTRAL INST-CLUSTERNov 6, 2026
Four institutional investors added to Bioventus positions in Q3 2026, totaling $1.8M in net…
The cluster is small in dollar terms relative to the $962M market cap and dominated by asset managers rather than activist or event-driven funds. The mixed signals and lack of insider buying suggest…
- NEUTRAL 8-KNov 2, 2026
Bioventus reported Q3 2026 revenue of $142.4M (+3% YoY), slightly below the $149.5M consensus, and…
The revenue miss and lowered top-end guidance are modest negatives, but the ongoing strategic alternatives review (including a potential sale) provides a counterbalancing catalyst. Watch for any…
- NEUTRAL PRESS-RELEASENov 2, 2026
Bioventus reported Q3 2026 non-GAAP EPS of $0.17, beating the $0.16 consensus by 6.3%, while…
Monitor the strategic alternatives review for potential M&A outcomes. The revenue miss and narrowed guidance suggest near-term headwinds, but the EPS beat and strong cash flow support the current…
All BVS filing & press-release reports (18)
- SC 13G reportNov 13, 2026
- INST-CLUSTER reportNov 6, 2026
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- SC 13G/A reportOct 27, 2026
- INST-CLUSTER reportAug 15, 2026
- PRESS-RELEASE reportAug 5, 2026
- 8-K reportAug 5, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 2, 2026
- 8-K reportMay 21, 2026
- COURT-RULING reportMay 8, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 28, 2026
- DEFA14A reportApr 22, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026